12:00 AM
 | 
Jul 18, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CHS-1701: Phase I data

Top-line data from a single-blind, crossover, U.S. Phase I trial in 122 healthy volunteers showed that a single dose of 6 mg subcutaneous CHS-1701 met...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >